Despite last year's sharp decline in approvals, registrations of two RNA drugs offer a window into the current state and possible future of drug development. Looking forward, the sector seeks greater clarity on the new presidential administration's priorities and the impact of new healthcare legislation. Chris Morrison reports.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Morrison, C. Nat. Biotechnol. 34, 129–132 (2016).
Anonymous. Nat. Biotechnol. 34, 1078 (2016).
Sheridan, C. Nat. Biotechnol. 34, 675–676 (2016).
Ratner, M. Nat. Biotechnol. 34, 789–790 (2016).
Shaffer, C. Nat. Biotechnol. 28, 187–188 (2010).
Morrison, C. Nat. Rev. Drug Discov. 14, 737–738 (2015).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Morrison, C. Fresh from the biotech pipeline—2016. Nat Biotechnol 35, 108–112 (2017). https://doi.org/10.1038/nbt.3783
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3783
This article is cited by
-
Opportunities in an Evolving Pharmaceutical Development Landscape: Product Differentiation of Biopharmaceutical Drug Products
Pharmaceutical Research (2021)
-
Fresh from the biotech pipeline—2017
Nature Biotechnology (2018)
-
Public biotech in 2016—the numbers
Nature Biotechnology (2017)
-
Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations
Gene Therapy (2017)
